Please login to the form below
Triple-negative breast cancer
This page shows the latest Triple-negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda combined with chemotherapy could benefit thousands of breast cancer patients
Women diagnosed with cases of early triple-negative breast cancer (TNBC) where the disease had not progressed beyond the breast and lymph nodes – markers in stage 2 and 3 – were treated ... pre-operative chemotherapy increases the treatment response
Latest news
-
Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy. ... The therapy is now indicated as monotherapy for the treatment of adults with unresectable (cannot be removed by
-
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
O’Day also focused on the company’s oncology drugs and said: “Our marketed portfolio continues to expand with four new country approvals for Trodelvy for metastatic triple-negative breast cancer, ... Sales of Tecartus (brexucabtagene autoleucel)
-
Merck receives first breast cancer approval in Europe for Keytruda
Merck’s anti-PD-1 therapy, Keytruda, is approved in the Europe Union for certain patients with triple-negative breast cancer plus chemotherapy. ... Triple-negative breast cancer (TNBC) is an aggressive form of the disease with a high recurrence rate
-
Gilead’s Trodelvy set for EU approval in breast cancer
unresectable or metastatic triple-negative breast cancer (TNBC). ... Gilead’s development programme for Trodelvy includes potential use in other TNBC and metastatic urothelial cancer, for hormone receptor-positive/human epidermal growth factor receptor
-
Green light for Amgen’s KRAS inhibitor in the UK
In response to the announcement of the early access scheme, cancer charity Breast Cancer NOW has criticised Gilead for failing to follow suit with Trodelvy (sacituzumab govitecan) in triple negative incurable ... Morgan. “These women don’t have time
More from news
Approximately 10 fully matching, plus 79 partially matching documents found.
Latest Intelligence
-
Patient diversity in clinical trials needs to be centre stage
For example, a few years back we created clinical trial advertising materials for a Triple Negative Breast Cancer study project and, as the condition adversely impacts the black population, we made ... opportunities.”. A blood cancer charity recently
-
Cortellis Drugs to Watch in 2020 report
9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
-
Deal Watch January 2018
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... Tucatinib is currently being
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug conjugate
-
Pharma deals during February 2014
MK-3475 was awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. ... BATON studies in colorectal cancer and metastatic triple negative breast cancer.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
July 2020: diversity and inclusion in clinical trials round-up
The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- The importance of beliefs in creative health engagement
- In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Almirall shares positive topline results from atopic dermatitis trials
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
PMHub
SEVEN STONES COLLECTIVE
Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
